data WORK.ANL2; infile datalines dsd truncover; input STUDYID:$50. USUBJID:$50. SUBJID:$10. SITEID:$50. REGION1:$20. COUNTRY:$10. ARM:$50. ARMN:32. ACTARM:$50. ACTARMN:32. RANDFL:$1. FASFL:$1. SAF01FL:$1. SAF02FL:$1. SAFFL:$1. STRAT1:$200. STRAT1N:32. STRAT2:$200. STRAT2N:32. TRTP:$40. TRTPN:32. ADT:DATE9. DSSEQ:32. APHASEN:32. APHASE:$40. PARCAT1:$200. PARCAT1N:32. PARAMCD:$8. PARAM:$200. PARAMN:32. AVALC:$200. AVAL:32. OTHER:$200. CDBR:$3.; datalines4; 16159A,16159A-BG1008-S1349,S1349,BG1008,Europe,BGR,BLINDED,5,BLINDED,5,N,N,,,Y,BGR,1,Risperidone,2,Risperidone,1,13FEB2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-BG1008-S1370,S1370,BG1008,Europe,BGR,BLINDED,5,BLINDED,5,Y,Y,,,Y,BGR,1,Risperidone,2,BLINDED,5,24MAR2017,10,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-BG1008-S1533,S1533,BG1008,Europe,BGR,BLINDED,5,BLINDED,5,N,Y,,,Y,BGR,1,Risperidone,2,Risperidone,1,28MAR2017,5,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-BG1008-S1710,S1710,BG1008,Europe,BGR,BLINDED,5,BLINDED,5,N,Y,,,Y,BGR,1,Olanzapine,1,Olanzapine,2,13JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Protocol violation,4,,No 16159A,16159A-BG1027-S1240,S1240,BG1027,Europe,BGR,BLINDED,5,BLINDED,5,N,Y,,,Y,BGR,1,Risperidone,2,Risperidone,1,04JAN2017,8,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-BG1027-S1240,S1240,BG1027,Europe,BGR,BLINDED,5,BLINDED,5,N,Y,,,Y,BGR,1,Risperidone,2,Risperidone,1,04JAN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-BG1028-S1570,S1570,BG1028,Europe,BGR,BLINDED,5,BLINDED,5,Y,N,,,Y,BGR,1,Risperidone,2,BLINDED,5,17MAY2017,10,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Non-compliance with IMP,3,,No 16159A,16159A-BG1029-S1834,S1834,BG1029,Europe,BGR,BLINDED,5,BLINDED,5,Y,Y,,,Y,BGR,1,Olanzapine,1,BLINDED,5,29AUG2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-BG1029-S1834,S1834,BG1029,Europe,BGR,BLINDED,5,BLINDED,5,Y,Y,,,Y,BGR,1,Olanzapine,1,BLINDED,5,29AUG2017,12,2,Period B,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Lost to follow-up,6,,No 16159A,16159A-BG1030-S1536,S1536,BG1030,Europe,BGR,BLINDED,5,BLINDED,5,Y,N,,,Y,BGR,1,Olanzapine,1,BLINDED,5,07JUN2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-CZ1013-S1555,S1555,CZ1013,Europe,CZE,BLINDED,5,BLINDED,5,N,Y,,,Y,CZE,3,Risperidone,2,Risperidone,1,04APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-CZ1023-S1237,S1237,CZ1023,Europe,CZE,BLINDED,5,BLINDED,5,Y,N,,,Y,CZE,3,Risperidone,2,BLINDED,5,28MAR2017,15,2,Period B,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-CZ1023-S1237,S1237,CZ1023,Europe,CZE,BLINDED,5,BLINDED,5,Y,N,,,Y,CZE,3,Risperidone,2,BLINDED,5,08FEB2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lack of efficacy,2,,No 16159A,16159A-CZ1023-S1237,S1237,CZ1023,Europe,CZE,BLINDED,5,BLINDED,5,Y,N,,,Y,CZE,3,Risperidone,2,BLINDED,5,08FEB2017,12,2,Period B,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Non-compliance with IMP,3,,No 16159A,16159A-CZ1023-S1237,S1237,CZ1023,Europe,CZE,BLINDED,5,BLINDED,5,Y,N,,,Y,CZE,3,Risperidone,2,BLINDED,5,08FEB2017,13,2,Period B,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-CZ1038-S1251,S1251,CZ1038,Europe,CZE,BLINDED,5,BLINDED,5,Y,N,,,Y,CZE,3,Risperidone,2,BLINDED,5,03MAR2017,13,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-FI1030-S1042,S1042,FI1030,Europe,FIN,BLINDED,5,BLINDED,5,Y,Y,,,Y,FIN,6,Risperidone,2,BLINDED,5,11OCT2016,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lack of efficacy,2,,No 16159A,16159A-FI1030-S1043,S1043,FI1030,Europe,FIN,BLINDED,5,BLINDED,5,Y,N,,,Y,FIN,6,Risperidone,2,BLINDED,5,20OCT2016,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lack of efficacy,2,,No 16159A,16159A-MX1005-S1624,S1624,MX1005,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,Y,,,Y,MEX,7,Olanzapine,1,Olanzapine,2,06JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-MX1005-S1752,S1752,MX1005,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,Y,,,Y,MEX,7,Olanzapine,1,Olanzapine,2,12JUL2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-MX1005-S1752,S1752,MX1005,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,Y,,,Y,MEX,7,Olanzapine,1,Olanzapine,2,12JUL2017,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Non-compliance with IMP,3,,No 16159A,16159A-MX1005-S1752,S1752,MX1005,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,Y,,,Y,MEX,7,Olanzapine,1,Olanzapine,2,12JUL2017,9,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Protocol violation,4,,No 16159A,16159A-MX1005-S1763,S1763,MX1005,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Risperidone,2,Risperidone,1,24JUL2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-MX1007-S1446,S1446,MX1007,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Olanzapine,1,Olanzapine,2,16MAR2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-MX1007-S1446,S1446,MX1007,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Olanzapine,1,Olanzapine,2,16MAR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Non-compliance with IMP,3,,No 16159A,16159A-MX1007-S1808,S1808,MX1007,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,Y,,,Y,MEX,7,Risperidone,2,Risperidone,1,27JUL2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-MX1011-S1607,S1607,MX1011,Rest of the World,MEX,BLINDED,5,BLINDED,5,Y,N,,,Y,MEX,7,Risperidone,2,BLINDED,5,02JUL2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-MX1015-S1720,S1720,MX1015,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Risperidone,2,Risperidone,1,03JUL2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,TREATMENT ASSIGNATION ERROR WHEN PROCESING IVRS AT BASELINE 1,No 16159A,16159A-MX1018-S1454,S1454,MX1018,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,Y,,,Y,MEX,7,Risperidone,2,Risperidone,1,26APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-MX1018-S1811,S1811,MX1018,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Risperidone,2,Risperidone,1,05SEP2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-MX1020-S1849,S1849,MX1020,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Risperidone,2,Risperidone,1,28AUG2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-MX1020-S1893,S1893,MX1020,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,Y,,,Y,MEX,7,Risperidone,2,Risperidone,1,24AUG2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,THE PATIENT DECIDES TO WITHDRAW FROM THE STUDY. MENTION NOT TO FEEL COMFORTABLE WITH THE AMOUNT OF BLOOD OBTAINED IN THE VISITS.,No 16159A,16159A-MX1021-S1340,S1340,MX1021,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Olanzapine,1,Olanzapine,2,09FEB2017,10,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Other,8,THE PATIENT'S MOTHER INFORMED US THAT THE PATIENT WAS NOT INTERESTED IN PARTICIPATING IN THE STUDY ANY MORE.,No 16159A,16159A-MX1021-S1340,S1340,MX1021,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Olanzapine,1,Olanzapine,2,13FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-MX1021-S1340,S1340,MX1021,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Olanzapine,1,Olanzapine,2,13FEB2017,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-MX1021-S1372,S1372,MX1021,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,Y,,,Y,MEX,7,Risperidone,2,Risperidone,1,15MAR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-MX1021-S1372,S1372,MX1021,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,Y,,,Y,MEX,7,Risperidone,2,Risperidone,1,15MAR2017,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Adverse event,1,,No 16159A,16159A-MX1021-S1430,S1430,MX1021,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Risperidone,2,Risperidone,1,03APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-MX1022-S1313,S1313,MX1022,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Risperidone,2,Risperidone,1,22FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-MX1022-S1443,S1443,MX1022,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,Y,,,Y,MEX,7,Olanzapine,1,Olanzapine,2,10APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-MX1022-S1460,S1460,MX1022,Rest of the World,MEX,BLINDED,5,BLINDED,5,Y,N,,,Y,MEX,7,Olanzapine,1,BLINDED,5,25APR2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-MX1022-S1640,S1640,MX1022,Rest of the World,MEX,BLINDED,5,BLINDED,5,N,N,,,Y,MEX,7,Olanzapine,1,Olanzapine,2,08JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-PL1027-S1241,S1241,PL1027,Europe,POL,BLINDED,5,BLINDED,5,Y,N,,,Y,POL,8,Risperidone,2,BLINDED,5,16FEB2017,13,2,Period B,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-PL1027-S1241,S1241,PL1027,Europe,POL,BLINDED,5,BLINDED,5,Y,N,,,Y,POL,8,Risperidone,2,BLINDED,5,13FEB2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-PL1051-S1216,S1216,PL1051,Europe,POL,BLINDED,5,BLINDED,5,N,Y,,,Y,POL,8,Risperidone,2,Risperidone,1,21DEC2016,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-PL1051-S1737,S1737,PL1051,Europe,POL,BLINDED,5,BLINDED,5,Y,N,,,Y,POL,8,Risperidone,2,BLINDED,5,16AUG2017,10,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-PL1058-S1205,S1205,PL1058,Europe,POL,BLINDED,5,BLINDED,5,N,N,,,Y,POL,8,Risperidone,2,Risperidone,1,20DEC2016,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-PL1058-S1493,S1493,PL1058,Europe,POL,BLINDED,5,BLINDED,5,N,Y,,,Y,POL,8,Risperidone,2,Risperidone,1,13MAR2017,5,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-PL1058-S1493,S1493,PL1058,Europe,POL,BLINDED,5,BLINDED,5,N,Y,,,Y,POL,8,Risperidone,2,Risperidone,1,13MAR2017,6,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Non-compliance with IMP,3,,No 16159A,16159A-PL1058-S1781,S1781,PL1058,Europe,POL,BLINDED,5,BLINDED,5,N,N,,,Y,POL,8,Risperidone,2,Risperidone,1,28JUN2017,8,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-PL1061-S1635,S1635,PL1061,Europe,POL,BLINDED,5,BLINDED,5,N,Y,,,Y,POL,8,Olanzapine,1,Olanzapine,2,18MAY2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-PL1061-S1635,S1635,PL1061,Europe,POL,BLINDED,5,BLINDED,5,N,Y,,,Y,POL,8,Olanzapine,1,Olanzapine,2,18MAY2017,7,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Lack of efficacy,2,,No 16159A,16159A-RS1003-S1371,S1371,RS1003,Europe,SRB,BLINDED,5,BLINDED,5,N,Y,,,Y,SRB,11,Olanzapine,1,Olanzapine,2,15MAR2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1008-S1614,S1614,RS1008,Europe,SRB,BLINDED,5,BLINDED,5,N,Y,,,Y,SRB,11,Olanzapine,1,Olanzapine,2,17MAY2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1008-S1707,S1707,RS1008,Europe,SRB,BLINDED,5,BLINDED,5,N,N,,,Y,SRB,11,Olanzapine,1,Olanzapine,2,22JUN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1008-S1753,S1753,RS1008,Europe,SRB,BLINDED,5,BLINDED,5,N,Y,,,Y,SRB,11,Olanzapine,1,Olanzapine,2,12JUL2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1008-S1767,S1767,RS1008,Europe,SRB,BLINDED,5,BLINDED,5,N,N,,,Y,SRB,11,Olanzapine,1,Olanzapine,2,20JUN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Protocol violation,4,,No 16159A,16159A-RS1008-S1840,S1840,RS1008,Europe,SRB,BLINDED,5,BLINDED,5,N,Y,,,Y,SRB,11,Risperidone,2,Risperidone,1,16AUG2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1009-S1683,S1683,RS1009,Europe,SRB,BLINDED,5,BLINDED,5,N,N,,,Y,SRB,11,Risperidone,2,Risperidone,1,19JUN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1009-S1886,S1886,RS1009,Europe,SRB,BLINDED,5,BLINDED,5,N,Y,,,Y,SRB,11,Olanzapine,1,Olanzapine,2,12SEP2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1010-S1434,S1434,RS1010,Europe,SRB,BLINDED,5,BLINDED,5,N,N,,,Y,SRB,11,Risperidone,2,Risperidone,1,03APR2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1010-S1441,S1441,RS1010,Europe,SRB,BLINDED,5,BLINDED,5,N,Y,,,Y,SRB,11,Risperidone,2,Risperidone,1,07MAR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RS1010-S1665,S1665,RS1010,Europe,SRB,BLINDED,5,BLINDED,5,N,N,,,Y,SRB,11,Risperidone,2,Risperidone,1,14JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1011-S1553,S1553,RS1011,Europe,SRB,BLINDED,5,BLINDED,5,N,Y,,,Y,SRB,11,Risperidone,2,Risperidone,1,06APR2017,5,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RS1011-S1553,S1553,RS1011,Europe,SRB,BLINDED,5,BLINDED,5,N,Y,,,Y,SRB,11,Risperidone,2,Risperidone,1,06APR2017,6,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Other,8,NON-COMPLIANCE TO STUDY PROTOCOL,No 16159A,16159A-RS1016-S1346,S1346,RS1016,Europe,SRB,BLINDED,5,BLINDED,5,N,N,,,Y,SRB,11,Risperidone,2,Risperidone,1,24JAN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RS1016-S1511,S1511,RS1016,Europe,SRB,BLINDED,5,BLINDED,5,N,N,,,Y,SRB,11,Risperidone,2,Risperidone,1,20APR2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1016-S1558,S1558,RS1016,Europe,SRB,BLINDED,5,BLINDED,5,N,Y,,,Y,SRB,11,Risperidone,2,Risperidone,1,09MAY2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1016-S1734,S1734,RS1016,Europe,SRB,BLINDED,5,BLINDED,5,N,N,,,Y,SRB,11,Olanzapine,1,Olanzapine,2,29JUN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RS1016-S1851,S1851,RS1016,Europe,SRB,BLINDED,5,BLINDED,5,N,N,,,Y,SRB,11,Risperidone,2,Risperidone,1,24JUL2017,5,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RS1017-S1359,S1359,RS1017,Europe,SRB,BLINDED,5,BLINDED,5,Y,Y,,,Y,SRB,11,Risperidone,2,BLINDED,5,20MAR2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RU1009-S1380,S1380,RU1009,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Olanzapine,1,Olanzapine,2,06MAR2017,9,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1009-S1584,S1584,RU1009,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Risperidone,2,Risperidone,1,11MAY2017,9,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RU1009-S1613,S1613,RU1009,Europe,RUS,BLINDED,5,BLINDED,5,Y,N,,,Y,RUS,10,Risperidone,2,BLINDED,5,31MAY2017,13,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-RU1009-S1613,S1613,RU1009,Europe,RUS,BLINDED,5,BLINDED,5,Y,N,,,Y,RUS,10,Risperidone,2,BLINDED,5,31MAY2017,14,2,Period B,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-RU1021-S1292,S1292,RU1021,Europe,RUS,BLINDED,5,BLINDED,5,N,N,,,Y,RUS,10,Risperidone,2,Risperidone,1,08FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RU1021-S1440,S1440,RU1021,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Risperidone,2,Risperidone,1,29MAR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1021-S1596,S1596,RU1021,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Olanzapine,1,Olanzapine,2,11MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1021-S1648,S1648,RU1021,Europe,RUS,BLINDED,5,BLINDED,5,Y,N,,,Y,RUS,10,Risperidone,2,BLINDED,5,03JUL2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lack of efficacy,2,,No 16159A,16159A-RU1021-S1648,S1648,RU1021,Europe,RUS,BLINDED,5,BLINDED,5,Y,N,,,Y,RUS,10,Risperidone,2,BLINDED,5,03JUL2017,12,2,Period B,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Adverse event,1,,No 16159A,16159A-RU1021-S1698,S1698,RU1021,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Risperidone,2,Risperidone,1,21JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1023-S1537,S1537,RU1023,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Risperidone,2,Risperidone,1,29MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1023-S1688,S1688,RU1023,Europe,RUS,BLINDED,5,BLINDED,5,Y,Y,,,Y,RUS,10,Olanzapine,1,BLINDED,5,21JUN2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,PATIENT CHANGES HIS PLACE OF RESIDENCE,No 16159A,16159A-RU1028-S1323,S1323,RU1028,Europe,RUS,BLINDED,5,BLINDED,5,N,N,,,Y,RUS,10,Olanzapine,1,Olanzapine,2,20FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1028-S1391,S1391,RU1028,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Olanzapine,1,Olanzapine,2,03MAR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RU1028-S1565,S1565,RU1028,Europe,RUS,BLINDED,5,BLINDED,5,N,N,,,Y,RUS,10,Risperidone,2,Risperidone,1,15MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1028-S1619,S1619,RU1028,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Olanzapine,1,Olanzapine,2,16MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1030-S1492,S1492,RU1030,Europe,RUS,BLINDED,5,BLINDED,5,Y,Y,,,Y,RUS,10,Olanzapine,1,BLINDED,5,07JUN2017,10,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RU1030-S1492,S1492,RU1030,Europe,RUS,BLINDED,5,BLINDED,5,Y,Y,,,Y,RUS,10,Olanzapine,1,BLINDED,5,07JUN2017,11,2,Period B,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Lack of efficacy,2,,No 16159A,16159A-RU1030-S1713,S1713,RU1030,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Olanzapine,1,Olanzapine,2,26JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1030-S1741,S1741,RU1030,Europe,RUS,BLINDED,5,BLINDED,5,N,N,,,Y,RUS,10,Risperidone,2,Risperidone,1,05JUN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RU1031-S1746,S1746,RU1031,Europe,RUS,BLINDED,5,BLINDED,5,Y,N,,,Y,RUS,10,Olanzapine,1,BLINDED,5,01AUG2017,10,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RU1049-S1783,S1783,RU1049,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Risperidone,2,Risperidone,1,12JUL2017,11,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Other,8,"DID NOT MEET CRITERIA FOR PERIOD ""B""",No 16159A,16159A-RU1049-S1783,S1783,RU1049,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Risperidone,2,Risperidone,1,12JUL2017,9,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1052-S1494,S1494,RU1052,Europe,RUS,BLINDED,5,BLINDED,5,Y,N,,,Y,RUS,10,Olanzapine,1,BLINDED,5,15MAY2017,14,2,Period B,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-RU1052-S1494,S1494,RU1052,Europe,RUS,BLINDED,5,BLINDED,5,Y,N,,,Y,RUS,10,Olanzapine,1,BLINDED,5,15MAY2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-RU1052-S1494,S1494,RU1052,Europe,RUS,BLINDED,5,BLINDED,5,Y,N,,,Y,RUS,10,Olanzapine,1,BLINDED,5,15MAY2017,12,2,Period B,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Lack of efficacy,2,,No 16159A,16159A-RU1052-S1535,S1535,RU1052,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Risperidone,2,Risperidone,1,04MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1052-S1802,S1802,RU1052,Europe,RUS,BLINDED,5,BLINDED,5,Y,N,,,Y,RUS,10,Olanzapine,1,BLINDED,5,14AUG2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lack of efficacy,2,,No 16159A,16159A-RU1052-S1802,S1802,RU1052,Europe,RUS,BLINDED,5,BLINDED,5,Y,N,,,Y,RUS,10,Olanzapine,1,BLINDED,5,14AUG2017,12,2,Period B,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Adverse event,1,,No 16159A,16159A-RU1053-S1422,S1422,RU1053,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Risperidone,2,Risperidone,1,30MAR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1053-S1503,S1503,RU1053,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Risperidone,2,Risperidone,1,10MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-RU1056-S1789,S1789,RU1056,Europe,RUS,BLINDED,5,BLINDED,5,N,Y,,,Y,RUS,10,Risperidone,2,Risperidone,1,22JUN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-RU1056-S1820,S1820,RU1056,Europe,RUS,BLINDED,5,BLINDED,5,N,N,,,Y,RUS,10,Olanzapine,1,Olanzapine,2,23AUG2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-SK1015-S1098,S1098,SK1015,Europe,SVK,BLINDED,5,BLINDED,5,Y,N,,,Y,SVK,12,Risperidone,2,BLINDED,5,13NOV2016,13,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,PI DECISION,No 16159A,16159A-SK1015-S1214,S1214,SK1015,Europe,SVK,BLINDED,5,BLINDED,5,N,Y,,,Y,SVK,12,Risperidone,2,Risperidone,1,13NOV2016,8,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,PI DECISION,No 16159A,16159A-SK1024-S1483,S1483,SK1024,Europe,SVK,BLINDED,5,BLINDED,5,N,Y,,,Y,SVK,12,Risperidone,2,Risperidone,1,12APR2017,11,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-SK1025-S1219,S1219,SK1025,Europe,SVK,BLINDED,5,BLINDED,5,Y,Y,,,Y,SVK,12,Risperidone,2,BLINDED,5,13MAR2017,13,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-SK1026-S1431,S1431,SK1026,Europe,SVK,BLINDED,5,BLINDED,5,N,N,,,Y,SVK,12,Risperidone,2,Risperidone,1,10APR2017,10,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-SK1026-S1431,S1431,SK1026,Europe,SVK,BLINDED,5,BLINDED,5,N,N,,,Y,SVK,12,Risperidone,2,Risperidone,1,10APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-SK1026-S1431,S1431,SK1026,Europe,SVK,BLINDED,5,BLINDED,5,N,N,,,Y,SVK,12,Risperidone,2,Risperidone,1,10APR2017,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-US1009-S1022,S1022,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,19AUG2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1009-S1081,S1081,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,03OCT2016,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1009-S1081,S1081,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,03OCT2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1009-S1121,S1121,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,07OCT2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1009-S1131,S1131,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,04NOV2016,11,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1009-S1131,S1131,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,04NOV2016,10,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Other,8,SUBJECT REFUSED ALL FOLLOW UP,No 16159A,16159A-US1009-S1131,S1131,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,04NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1009-S1131,S1131,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,04NOV2016,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-US1009-S1213,S1213,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,31JAN2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1009-S1213,S1213,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,15DEC2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1009-S1325,S1325,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,15FEB2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1009-S1325,S1325,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,15FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1009-S1376,S1376,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,27FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1009-S1679,S1679,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,08JUN2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1009-S1679,S1679,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,08JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1009-S1757,S1757,US1009,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,03JUL2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1041-S1089,S1089,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,03OCT2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1041-S1090,S1090,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,14OCT2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1041-S1104,S1104,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,12OCT2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1041-S1114,S1114,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,27OCT2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,SUBJECT TOOK EXCLUSIONARY MEDICATION,No 16159A,16159A-US1041-S1250,S1250,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,23JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1041-S1520,S1520,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,11MAY2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1041-S1529,S1529,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,21APR2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1041-S1601,S1601,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,17MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1041-S1702,S1702,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,20JUN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1041-S1711,S1711,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,23JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1041-S1742,S1742,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,20JUL2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1041-S1750,S1750,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,22JUN2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1041-S1750,S1750,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,22JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1041-S1797,S1797,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,03AUG2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1041-S1854,S1854,US1041,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,01SEP2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1046-S1036,S1036,US1046,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,19SEP2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1046-S1063,S1063,US1046,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,22SEP2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1046-S1117,S1117,US1046,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,07NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1046-S1117,S1117,US1046,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,07NOV2016,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Lack of efficacy,2,,No 16159A,16159A-US1046-S1117,S1117,US1046,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,07NOV2016,9,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Non-compliance with IMP,3,,No 16159A,16159A-US1046-S1236,S1236,US1046,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,04JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1046-S1453,S1453,US1046,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,Y,,,Y,USA,14,Risperidone,2,BLINDED,5,08MAY2017,10,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1046-S1633,S1633,US1046,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,06JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1046-S1740,S1740,US1046,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,17JUL2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1046-S1863,S1863,US1046,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,,,PENDING,999,15AUG2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,NONCOMPLIANCE WITH PROTOCOL,No 16159A,16159A-US1062-S1074,S1074,US1062,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,07OCT2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1062-S1135,S1135,US1062,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,17APR2017,13,2,Period B,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Other,8,NOT DONE DUE TO SITE ERROR,No 16159A,16159A-US1062-S1135,S1135,US1062,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,27JAN2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lack of efficacy,2,,No 16159A,16159A-US1062-S1562,S1562,US1062,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,29MAR2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lack of efficacy,2,,No 16159A,16159A-US1065-S1023,S1023,US1065,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,,,PENDING,999,27JUL2016,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lost to follow-up,6,,No 16159A,16159A-US1065-S1039,S1039,US1065,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,23SEP2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1065-S1228,S1228,US1065,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,14MAR2017,13,2,Period B,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Lost to follow-up,6,,No 16159A,16159A-US1065-S1228,S1228,US1065,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,16FEB2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1065-S1245,S1245,US1065,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,27JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1065-S1253,S1253,US1065,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,27JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1065-S1258,S1258,US1065,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,23JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1065-S1388,S1388,US1065,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,07MAR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lost to follow-up,6,,No 16159A,16159A-US1065-S1451,S1451,US1065,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,,,PENDING,999,23FEB2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lost to follow-up,6,,No 16159A,16159A-US1104-S1124,S1124,US1104,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,Y,,,Y,USA,14,Olanzapine,1,BLINDED,5,01FEB2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1104-S1177,S1177,US1104,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,06JAN2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Lost to follow-up,6,,No 16159A,16159A-US1104-S1177,S1177,US1104,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,05DEC2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1104-S1474,S1474,US1104,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,20APR2017,8,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Other,8,PATIENT DID NOT COMPLETE SAFETY FOLLOW UP DUE TO LOST TO FOLLOW UP.,No 16159A,16159A-US1104-S1474,S1474,US1104,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,20APR2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1104-S1716,S1716,US1104,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,30JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1104-S1796,S1796,US1104,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,01AUG2017,10,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1104-S1809,S1809,US1104,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,03AUG2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1114-S1003,S1003,US1114,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,05JUL2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Non-compliance with IMP,3,,No 16159A,16159A-US1114-S1012,S1012,US1114,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,22JUN2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1114-S1109,S1109,US1114,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,30NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1114-S1109,S1109,US1114,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,30NOV2016,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1114-S1261,S1261,US1114,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,07FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1114-S1652,S1652,US1114,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,08JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1114-S1668,S1668,US1114,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,15JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1114-S1795,S1795,US1114,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,03AUG2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1118-S1402,S1402,US1118,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,29MAR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1124-S1018,S1018,US1124,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,08SEP2016,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1124-S1018,S1018,US1124,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,08SEP2016,12,2,Period B,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Lack of efficacy,2,,No 16159A,16159A-US1124-S1033,S1033,US1124,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,25AUG2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1124-S1044,S1044,US1124,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,08SEP2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,SUB THERAPEUTIC BLOOD LEVELS OF OLANZAPINE,No 16159A,16159A-US1124-S1044,S1044,US1124,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,08SEP2016,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1124-S1085,S1085,US1124,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,Y,,,Y,USA,14,Risperidone,2,BLINDED,5,08NOV2016,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,NEEDED ANTIDEPRESSANT MEDICATION FOR A/E OF DEPRESSIVE SYMPTOMS AND SUICIDAL IDEATION.,No 16159A,16159A-US1124-S1118,S1118,US1124,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,02NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1124-S1166,S1166,US1124,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,27OCT2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1124-S1166,S1166,US1124,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,27OCT2016,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Non-compliance with IMP,3,,No 16159A,16159A-US1124-S1298,S1298,US1124,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,06FEB2017,10,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1124-S1373,S1373,US1124,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Olanzapine,1,BLINDED,5,19APR2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1129-S1132,S1132,US1129,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,,,PENDING,999,05OCT2016,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lost to follow-up,6,,No 16159A,16159A-US1129-S1269,S1269,US1129,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,23JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1129-S1514,S1514,US1129,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,21APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1130-S1145,S1145,US1130,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,22NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1130-S1188,S1188,US1130,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,12DEC2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1130-S1192,S1192,US1130,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,13DEC2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1130-S1560,S1560,US1130,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,10APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1130-S1618,S1618,US1130,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,26JUN2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Lost to follow-up,6,,No 16159A,16159A-US1130-S1618,S1618,US1130,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,17MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1130-S1628,S1628,US1130,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,01JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1171-S1001,S1001,US1171,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,23MAY2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1171-S1002,S1002,US1171,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,03JUN2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1171-S1002,S1002,US1171,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,03JUN2016,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Non-compliance with IMP,3,,No 16159A,16159A-US1171-S1053,S1053,US1171,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,22SEP2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1171-S1663,S1663,US1171,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,13JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1190-S1506,S1506,US1190,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,26APR2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1190-S1506,S1506,US1190,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,26APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1190-S1524,S1524,US1190,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,08MAY2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1190-S1524,S1524,US1190,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,08MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1244-S1076,S1076,US1244,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,29AUG2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,IN PI'S ESTIMATION SUBJECT WAS NON COMPLIANT WITH MEDICATION (FOR 5 DAYS) LAST DOSE ON 8/24/2016. RE-STARTED HIMSELF ON OLANZAPINE (HIS PRIOR MEDICATION) ON 8/25/2016.,No 16159A,16159A-US1244-S1223,S1223,US1244,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,06DEC2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1244-S1639,S1639,US1244,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,04MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lost to follow-up,6,,No 16159A,16159A-US1318-S1024,S1024,US1318,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,24AUG2016,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Lost to follow-up,6,,No 16159A,16159A-US1318-S1024,S1024,US1318,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,24AUG2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1318-S1028,S1028,US1318,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,25AUG2016,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Lost to follow-up,6,,No 16159A,16159A-US1318-S1028,S1028,US1318,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,25AUG2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1318-S1078,S1078,US1318,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,14SEP2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lost to follow-up,6,,No 16159A,16159A-US1318-S1112,S1112,US1318,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,26SEP2016,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1318-S1546,S1546,US1318,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,05MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1319-S1108,S1108,US1319,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,01NOV2016,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Lost to follow-up,6,,No 16159A,16159A-US1319-S1108,S1108,US1319,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,01NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1319-S1120,S1120,US1319,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,11NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1319-S1134,S1134,US1319,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,21NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1368-S1017,S1017,US1368,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,16AUG2016,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1368-S1101,S1101,US1368,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,04NOV2016,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lost to follow-up,6,,No 16159A,16159A-US1368-S1299,S1299,US1368,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,26JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1368-S1326,S1326,US1368,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Olanzapine,1,BLINDED,5,30MAR2017,10,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1384-S1050,S1050,US1384,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,19SEP2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1384-S1361,S1361,US1384,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,03FEB2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1384-S1805,S1805,US1384,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,02AUG2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1390-S1168,S1168,US1390,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,08DEC2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1391-S1522,S1522,US1391,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,02MAY2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1391-S1760,S1760,US1391,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,06JUL2017,8,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1391-S1799,S1799,US1391,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,18JUL2017,10,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Other,8,LACK OF EFFICACY,No 16159A,16159A-US1391-S1799,S1799,US1391,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,13JUL2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lack of efficacy,2,,No 16159A,16159A-US1391-S1799,S1799,US1391,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,13JUL2017,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Adverse event,1,,No 16159A,16159A-US1392-S1046,S1046,US1392,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,13SEP2016,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Other,8,PATIENT DID NOT QUALIFY FOR RANDOMIZATION INTO PART B,No 16159A,16159A-US1392-S1046,S1046,US1392,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,13SEP2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1392-S1470,S1470,US1392,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,25APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1392-S1594,S1594,US1392,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,24APR2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1392-S1594,S1594,US1392,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,24APR2017,7,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-US1392-S1765,S1765,US1392,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,11SEP2017,11,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Other,8,SUBJECT IS EARLY TERM,No 16159A,16159A-US1392-S1765,S1765,US1392,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,24JUL2017,9,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1394-S1234,S1234,US1394,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,09FEB2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Lost to follow-up,6,,No 16159A,16159A-US1394-S1234,S1234,US1394,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,09FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1394-S1267,S1267,US1394,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,24JAN2017,8,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1394-S1267,S1267,US1394,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,24JAN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1394-S1469,S1469,US1394,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,03MAR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1398-S1176,S1176,US1398,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,07DEC2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1398-S1666,S1666,US1398,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,06JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1399-S1061,S1061,US1399,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,17AUG2016,10,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1399-S1061,S1061,US1399,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,17AUG2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1399-S1061,S1061,US1399,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,17AUG2016,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Adverse event,1,,No 16159A,16159A-US1399-S1066,S1066,US1399,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,22SEP2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1399-S1091,S1091,US1399,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,11OCT2016,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1399-S1260,S1260,US1399,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,11JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1399-S1334,S1334,US1399,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,16FEB2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1399-S1508,S1508,US1399,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,10APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1399-S1785,S1785,US1399,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,Y,,,Y,USA,14,Risperidone,2,BLINDED,5,09SEP2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,PATIENT MISSED REQUIRED VISITS AND WAS OUTSIDE OF PROTOCOL DEFINED WINDOW.,No 16159A,16159A-US1401-S1515,S1515,US1401,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,07MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1401-S1515,S1515,US1401,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,07MAY2017,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Non-compliance with IMP,3,,No 16159A,16159A-US1401-S1515,S1515,US1401,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,07MAY2017,9,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-US1402-S1029,S1029,US1402,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,13SEP2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1402-S1030,S1030,US1402,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,07SEP2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1402-S1105,S1105,US1402,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,04NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1402-S1294,S1294,US1402,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,04JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1402-S1305,S1305,US1402,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,16FEB2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1402-S1305,S1305,US1402,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,16FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1402-S1311,S1311,US1402,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,23FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1402-S1317,S1317,US1402,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,Y,,,Y,USA,14,Risperidone,2,BLINDED,5,27MAR2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Non-compliance with IMP,3,,No 16159A,16159A-US1402-S1369,S1369,US1402,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,07MAR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1402-S1693,S1693,US1402,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,20JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1403-S1107,S1107,US1403,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,18OCT2016,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1403-S1195,S1195,US1403,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Olanzapine,1,BLINDED,5,20DEC2016,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1403-S1623,S1623,US1403,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,31MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1404-S1257,S1257,US1404,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,20JAN2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1404-S1257,S1257,US1404,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,20JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1405-S1382,S1382,US1405,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,24MAR2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1416-S1405,S1405,US1416,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,21MAR2017,10,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1416-S1686,S1686,US1416,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,24MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1423-S1185,S1185,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,09NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1423-S1185,S1185,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,09NOV2016,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Non-compliance with IMP,3,,No 16159A,16159A-US1423-S1185,S1185,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,09NOV2016,9,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-US1423-S1200,S1200,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,28NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1423-S1232,S1232,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,20DEC2016,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Other,8,SUBJECT UNABLE TO COME TO SITE DUE TO CURRENT HOSPITALIZATION FOR SAE STARTED 01 JAN 2017 UPDATE 5/8/17: SUBJECT REMAINS IN A PHYSICAL REHAB CENTER FOR ANKLE INJURIES FOR AN UNDETERMINED DURATION,No 16159A,16159A-US1423-S1232,S1232,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,20DEC2016,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1423-S1243,S1243,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,06JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1423-S1273,S1273,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,01FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1423-S1275,S1275,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,30JAN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1423-S1335,S1335,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,06MAR2017,10,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Lost to follow-up,6,,No 16159A,16159A-US1423-S1335,S1335,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,17FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1423-S1335,S1335,US1423,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,17FEB2017,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1133,S1133,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,04NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1426-S1146,S1146,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,10NOV2016,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1146,S1146,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,10NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1426-S1149,S1149,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,07NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1426-S1167,S1167,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,18NOV2016,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Other,8,PATIENT MOVED OUT OF STATE,No 16159A,16159A-US1426-S1167,S1167,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,18NOV2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1426-S1217,S1217,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,06DEC2016,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1279,S1279,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,07FEB2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1279,S1279,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,07FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1426-S1344,S1344,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,18FEB2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1344,S1344,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,18FEB2017,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Other,8,"SUBJECT IN VIRGINIA WITH FAMILY FOR FAMILY EMERGENCY - PER LAST CONTACT ON 06MAR2017, SUBJECT STATES WILL NOT BE RETURNING FOR AT LEAST 6 MONTHS. LAST CONFIRMED DOSE PER SUBJECT 12FEB2017",No 16159A,16159A-US1426-S1363,S1363,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,26JAN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1364,S1364,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,Y,,,Y,USA,14,Olanzapine,1,BLINDED,5,05APR2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1409,S1409,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,20MAR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1426-S1530,S1530,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,01MAY2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1530,S1530,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,24APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1426-S1575,S1575,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,03MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1426-S1581,S1581,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,18JUL2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Non-compliance with IMP,3,,No 16159A,16159A-US1426-S1582,S1582,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,06JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1426-S1589,S1589,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,18APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1609,S1609,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,27APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1426-S1609,S1609,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,27APR2017,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1642,S1642,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,05MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1651,S1651,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,10MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1725,S1725,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,Y,,,Y,USA,14,Risperidone,2,BLINDED,5,31JUL2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Withdrawal of consent,5,,No 16159A,16159A-US1426-S1845,S1845,US1426,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,18AUG2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1441-S1412,S1412,US1441,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,06APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1443-S1692,S1692,US1443,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,16JUN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1444-S1490,S1490,US1444,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,18APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1444-S1501,S1501,US1444,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,07AUG2017,13,2,Period B,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Other,8,SUBJECT WAS OUT OF WINDOW FOR VISIT 12 AND IT WAS NOT POSSIBLE TO COMPLETE EFFICACY FOLLOW-UP VISIT.,No 16159A,16159A-US1444-S1501,S1501,US1444,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,12JUL2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Non-compliance with IMP,3,,No 16159A,16159A-US1444-S1521,S1521,US1444,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,18APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1444-S1847,S1847,US1444,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,22AUG2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,POSITIVE URINE DRUG SCREEN,No 16159A,16159A-US1451-S1497,S1497,US1451,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,13APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Non-compliance with IMP,3,,No 16159A,16159A-US1451-S1573,S1573,US1451,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,24MAY2017,11,2,Period B,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lack of efficacy,2,,No 16159A,16159A-US1451-S1573,S1573,US1451,USA/Canada,USA,BLINDED,5,BLINDED,5,Y,N,,,Y,USA,14,Risperidone,2,BLINDED,5,24MAY2017,12,2,Period B,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Adverse event,1,,No 16159A,16159A-US1451-S1632,S1632,US1451,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,17MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Protocol violation,4,,No 16159A,16159A-US1451-S1676,S1676,US1451,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,28APR2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Lost to follow-up,6,,No 16159A,16159A-US1451-S1684,S1684,US1451,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Olanzapine,1,Olanzapine,2,26MAY2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1454-S1754,S1754,US1454,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,01JUN2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Adverse event,1,,No 16159A,16159A-US1454-S1754,S1754,US1454,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,01JUN2017,7,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-US1454-S1774,S1774,US1454,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,24JUL2017,6,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1459-S1731,S1731,US1459,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,26JUL2017,9,1,Period A,Discontinuation from Study,2,DCSREAS,Reason for withdrawal from study,3,Withdrawal of consent,5,,No 16159A,16159A-US1459-S1731,S1731,US1459,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Risperidone,2,Risperidone,1,28JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Did not fulfill inclusion criteria for Period B,7,,No 16159A,16159A-US1459-S1798,S1798,US1459,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,26JUN2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,THIS WAS A DUPLICATE SUBJECT,No 16159A,16159A-US1459-S1798,S1798,US1459,USA/Canada,USA,BLINDED,5,BLINDED,5,N,N,,,Y,USA,14,Risperidone,2,Risperidone,1,26JUN2017,8,1,Period A,Discontinuation from Treatment,1,SECREAS,Secondary reason for withdrawal from trt,2,Withdrawal of consent,5,,No 16159A,16159A-US1459-S1800,S1800,US1459,USA/Canada,USA,BLINDED,5,BLINDED,5,N,Y,,,Y,USA,14,Olanzapine,1,Olanzapine,2,27JUL2017,7,1,Period A,Discontinuation from Treatment,1,PRIMREAS,Primary reason for withdrawal from trt,1,Other,8,SPONSOR REQUESTED,No ;;;;